{"id":"https://genegraph.clinicalgenome.org/r/94c1f649-fd76-43c0-aa07-8466bf626541v1.0","type":"EvidenceStrengthAssertion","dc:description":"The *TEK* gene was first reported in relation to primary congenital glaucoma in 2016, with the publication of ten affected families of diverse ancestries (PMID: 27270174). Affected individuals frequently present at birth or in early childhood, although some families with such cases also include other members with late-onset disease, indicating variable expressivity and incomplete penetrance (PMID: 27270174). Affected individuals present in one or both eyes with increased corneal diameter, corneal edema, increased intraocular pressure, increased cup-to-disc ratio of the optic nerve, and/or Haab striae. Per criteria outlined by the ClinGen Lumping & Splitting Working Group, the molecular mechanism (loss-of-function) was found to be distinct from patients diagnosed with multiple cutaneous and mucosal venous malformations, who similarly exhibit an autosomal dominant mode of inheritance but harbor gain-of-function variants in *TEK* that cluster within the protein kinase domain. In addition, the phenotypic differences between the two groups of cases appeared to represent separate disease entities rather than a single spectrum of disease. Therefore, cases caused by inherited *TEK* variants have been split into two separately-curated disease entities, referred to as primary congenital glaucoma-3E (MONDO:0014998, MIM #617272), and multiple cutaneous and mucosal venous malformations (MONDO:0010842, MIM #600195).  In order to acknowledge the broader spectrum of onset and variable expressivity of the ocular disease entity, it is referred to in this curation as *TEK*-related primary glaucoma (MONDO:0800182).\n\nThirteen patient-associated variants have been scored as part of this curation (four nonsense, seven missense, and two disrupting splicing), which have been collectively reported in thirteen probands in three publications (PMID: 27270174, PMID: 33027505, PMID: 34956319). All thirteen probands were heterozygous for their respective variants. The mechanism of pathogenicity appears to be monoallelic loss-of-function, caused by null and/or hypomorphic variants. Patient-associated missense variants exhibited diverse functional defects ranging from reduced autophosphorylation or defective ligand response to decreased expression, stability, or solubility (PMID: 27270174, PMID: 33027505, PMID: 34956319). It is important to note that the penetrance of *TEK* variants appears to be influenced in some cases by the presence of modifier alleles in related genes such as *CYP1B1* (PMID: 28620713), *SVEP1* (PMID: 33027505), and possibly *LTBP2* (PMID: 34956319), consistent with the possibility of digenic inheritance. However, none of the cases included in this curation were reported to harbor a potential modifier allele in another glaucoma-related locus. Segregation evidence was not available in these publications and has not contributed to the scoring of the gene-disease relationship.\n\nThis gene-disease association is also supported by experimental evidence. *TEK* encodes a receptor tyrosine kinase stimulated by angiopoietin ligands to transduce signals that regulate endothelial cell behavior and the development and maintenance of Schlemm's canal, an endothelial structure responsible for aqueous humor drainage in the eye (PMID: 18425120). This function may be mediated in part through upregulation of the *PROX1* gene, which encodes a downstream effector that positively regulates Schlemmâ€™s canal and lymphatic cell fate (PMID: 28920924). *TEK* is highly expressed in ocular tissues (PMID: 30239781) and within the endothelial cells of Schlemm's canal in particular (PMID: 25051267). Mice with heterozygous disruption of the orthologous gene exhibit defects in Schlemm's canal, hypoplastic trabecular meshwork, impaired aqueous humor outflow, and increased intraocular pressure, (PMID: 27270174, PMID: 28920924), as well as enlargement of the anterior chamber (PMID: 25202984).\n\nIn summary, *TEK* is definitively associated with *TEK*-related primary glaucoma. This has been repeatedly demonstrated in both research and diagnostic settings, and has been upheld over time without the emergence of contradictory evidence, leading to a Definitive classification. This classification was approved by the ClinGen Glaucoma and Neuro-Ophthalmology Gene Curation Expert Panel on August 18th, 2022 (SOP Version 9).","dc:isVersionOf":"https://genegraph.clinicalgenome.org/r/94c1f649-fd76-43c0-aa07-8466bf626541","GCISnapshot":"https://genegraph.clinicalgenome.org/r/20f13e3f-f927-46c1-b5ed-919f696a7687","calculatedEvidenceStrength":"Definitive","contributions":[{"id":"https://genegraph.clinicalgenome.org/r/20f13e3f-f927-46c1-b5ed-919f696a7687_publish_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10077","date":"2022-11-21T17:47:42.309Z","role":"Publisher"},{"id":"https://genegraph.clinicalgenome.org/r/20f13e3f-f927-46c1-b5ed-919f696a7687_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10077","date":"2022-08-18T16:00:00.000Z","role":"Approver"}],"evidence":[{"id":"https://genegraph.clinicalgenome.org/r/20f13e3f-f927-46c1-b5ed-919f696a7687_overall_genetic_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/b2c0bbab-0116-485d-82de-8ef1ccef252d","type":"EvidenceLine","dc:description":"The variant has been up-scored for extensive evidence of a deleterious effects on the gene product.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/b2c0bbab-0116-485d-82de-8ef1ccef252d_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"NM_000459.5(TEK):c.698G>A (p.Cys233Tyr) is a missense variant shown by the authors to disrupt TEK autophosphorylation (Figures 2A-2C), prevent localization to the plasma membrane (Figure 3A), and be subject to enhanced degradation leading to decreased abundance (Figure 3C).","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/b2c0bbab-0116-485d-82de-8ef1ccef252d_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/27270174","allele":{"id":"https://genegraph.clinicalgenome.org/r/0672e13d-6dc7-48c1-be6b-b6a07cc82909","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000459.5(TEK):c.698G>A (p.Cys233Tyr)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA373124460"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/f3fe5951-3049-4690-a19f-cff99214522a","type":"EvidenceLine","dc:description":"NM_000459.5(TEK):c.921C>A (p.Tyr307Ter) is a nonsense variant in exon 7 of 24 and is predicted to trigger nonsense-mediated decay or at least truncate the C-terminal 73% of the protein product.","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/f3fe5951-3049-4690-a19f-cff99214522a_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/27270174","allele":{"id":"https://genegraph.clinicalgenome.org/r/87d5caba-6c7e-4ce7-9a02-f39a3d737c2c","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000459.5(TEK):c.921C>A (p.Tyr307Ter)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA16043929"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/329cae05-7f73-4f35-bb6c-38754c3e2303","type":"EvidenceLine","dc:description":"NM_000459.5(TEK):c.2950G>T (p.Gly984Ter) is a nonsense variant in exon 18 of 24 that is predicted to trigger nonsense-mediated decay or at least truncate the C-terminal 13% of the protein product.","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/329cae05-7f73-4f35-bb6c-38754c3e2303_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/27270174","allele":{"id":"https://genegraph.clinicalgenome.org/r/d4c995cc-62f1-4b1f-b231-13034d3d605e","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NC_000009.12:g.27213556G>T (GRCh38)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA373123828"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/91d60e74-c8b3-4f09-9432-5eff8f20a072","type":"EvidenceLine","dc:description":"The score is appropriate given the characterized impact on the protein product.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/91d60e74-c8b3-4f09-9432-5eff8f20a072_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"NM_000459.5(TEK):c.1624+5G>A (p.Val497_Ile541del) is a variant disrupting a donor splice site in intron 11 and is shown by exon trapping (Figure 3) to trigger in-frame skipping of exon 11, encoding amino acids 497 to 541 (removing 4% of the protein product).","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/91d60e74-c8b3-4f09-9432-5eff8f20a072_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/33027505","allele":{"id":"https://genegraph.clinicalgenome.org/r/caa705c7-797f-47ca-b997-87821dd37940","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NC_000009.12:g.27192628G>A (GRCh38)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA587126277"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/c2777140-af80-417c-9b5a-efaf48751fff","type":"EvidenceLine","dc:description":"The variant has been moderately up-scored to account for the evidence of a deleterious effect on TEK phosphorylation.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/c2777140-af80-417c-9b5a-efaf48751fff_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"NM_000459.5(TEK):c.578A>G (p.Tyr193Cys) is a missense variant in exon 4 and is shown by the authors to exhibit defective phosphorylation (Figure 4a).","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/c2777140-af80-417c-9b5a-efaf48751fff_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/33027505","allele":{"id":"https://genegraph.clinicalgenome.org/r/7c5acad2-7314-4504-b49a-c90fe7893ce9","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000459.5(TEK):c.578A>G (p.Tyr193Cys)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/804257"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/4f548077-d246-49cb-b160-88b6c1812710","type":"EvidenceLine","dc:description":"The moderate up-scoring is appropriate, as the variant has evidence of inability to phosphorylate, but not of insolubility like the other patient-associated variants.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/4f548077-d246-49cb-b160-88b6c1812710_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"NM_000459.5(TEK):c.3103G>C (p.Gly1035Arg) is a missense variant in exon 20 and is shown by the authors to exhibit defective phosphorylation (Figure 4a, 4f).","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/4f548077-d246-49cb-b160-88b6c1812710_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/33027505","allele":{"id":"https://genegraph.clinicalgenome.org/r/5586980c-eab6-4f31-bf0f-72c60b50c7a0","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000459.5(TEK):c.3103G>C (p.Gly1035Arg)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA373127469"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/720c503a-b535-4353-ba5d-cdef630f5db0","type":"EvidenceLine","dc:description":"The variant has been scored for the convincing functional evidence despite the consanguinity of the patient's parents.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/720c503a-b535-4353-ba5d-cdef630f5db0_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"NM_000459.5(TEK):c.407G>T (p.Gly136Val) is a missense variant in exon 3 of 24 and is shown by the authors to be expressed at approximately wild-type levels but to exhibit increased insolubility (Figure 4b) and localization to a proteasome-associated region of the cytoplasm rather than throughout the cytoplasm (Figure 4c). This helps explain the inability of the variant to properly phosphorylate (Figure 4a).","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/720c503a-b535-4353-ba5d-cdef630f5db0_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/33027505","allele":{"id":"https://genegraph.clinicalgenome.org/r/b00bcfd1-89c8-491a-91ee-384ae8134097","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000459.5(TEK):c.407G>T (p.Gly136Val)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA373122492"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/afaebb1f-1eb5-47a1-a4ed-5666e7e32c96","type":"EvidenceLine","dc:description":"Moderate up-scoring has been performed to account for the deleterious effect of the variant on TEK phosphorylation.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/afaebb1f-1eb5-47a1-a4ed-5666e7e32c96_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"NM_000459.5(TEK):c.731C>G (p.Pro244Arg) is a missense variant in exon 5 and is shown by the authors to exhibit defective phosphorylation (Figure 4a).","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/afaebb1f-1eb5-47a1-a4ed-5666e7e32c96_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/33027505","allele":{"id":"https://genegraph.clinicalgenome.org/r/b7d16a27-2f1f-4d56-aa6c-79cf02cb7aec","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000459.5(TEK):c.731C>G (p.Pro244Arg)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA373124635"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/5918c1a8-d06a-466f-99c1-ec70cf0826b5","type":"EvidenceLine","dc:description":"The variant was up-scored for the functional evidence of deleterious impact but was only done so conservatively due to the genotyping having been limited to only a few genes.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/5918c1a8-d06a-466f-99c1-ec70cf0826b5_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"NM_000459.5(TEK):c.730C>T (p.Pro244Ser) is a missense variant in exon 5 of 24 that is shown by the authors to reduce soluble expression of the gene product (Figure 1A), particularly its immunofluorescent signal (Figure 4A).","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/5918c1a8-d06a-466f-99c1-ec70cf0826b5_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/34956319","allele":{"id":"https://genegraph.clinicalgenome.org/r/251edb82-5713-42ab-a3d8-5366194b5207","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000459.5(TEK):c.730C>T (p.Pro244Ser)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA373124627"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/69bcd94c-5432-442c-80c3-37f0e8770504","type":"EvidenceLine","dc:description":"The patient has only been moderately up-scored, as this is the only suspected deleterious variant from the study shown to disrupt ligand response, while other variants of interest exert a deleterious impact through a different mechanism.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/69bcd94c-5432-442c-80c3-37f0e8770504_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"NM_000459.5(TEK):c.1832A>G (p.Tyr611Cys) is a missense variant in exon 12 shown by the authors to be expressed, autophosphorylated, and localized comparably to wild-type TEK (Figures 2A-2C, 3A), but to lack the ability to respond to ANGPT1 stimulation (Figures 3A, S10), consistent with disruption of the ligand binding domain.","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/69bcd94c-5432-442c-80c3-37f0e8770504_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/27270174","allele":{"id":"https://genegraph.clinicalgenome.org/r/9302bedb-9e97-4fa7-90ce-8035af968ae5","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000459.5(TEK):c.1832A>G (p.Tyr611Cys)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA373113665"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/2929b22c-6e59-465d-9bfc-549db5f210e9","type":"EvidenceLine","dc:description":"NM_000459.5(TEK):c.448G>T (p.Glu150Ter) is a nonsense variant in exon 3 of 24 that is predicted to trigger nonsense-mediated decay or at least truncate the C-terminal 87% of the protein product.","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/2929b22c-6e59-465d-9bfc-549db5f210e9_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/27270174","allele":{"id":"https://genegraph.clinicalgenome.org/r/657cdd6d-84ca-40f5-b69f-bcb272f6fc4d","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000459.5(TEK):c.448G>T (p.Glu150Ter)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA16043930"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"paternityMaternityConfirmed":"No","zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/b7e683e8-2094-4962-8f97-f3e9fcd7c462","type":"EvidenceLine","dc:description":"NM_000459.5(TEK):c.2712C>G (p.Tyr904Ter) is a nonsense variant in exon 17 of 24 and is predicted to trigger nonsense-mediated decay or at least truncate the C-terminal 20% of the protein product.","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/b7e683e8-2094-4962-8f97-f3e9fcd7c462_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/33027505","allele":{"id":"https://genegraph.clinicalgenome.org/r/6fd107b6-1dce-4957-a632-3d7ae00d5c45","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000459.5(TEK):c.2712C>G (p.Tyr904Ter)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA373122770"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/aa4597ba-9517-41f9-928d-979dfa309cca","type":"EvidenceLine","dc:description":"The variant has been up-scored for the functional evidence indicating a deleterious effect at the mRNA level.","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/aa4597ba-9517-41f9-928d-979dfa309cca_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"NM_000459.5:c.760+2T>C is a canonical splice site variant in intron 5 shown by the authors in an exon trapping assay to disrupt mRNA splicing by abolishing a splice donor site and triggering use of a cryptic splice site that introduces a premature termination codon (Figure 4). This is predicted to trigger nonsense-mediated decay or at least truncate the C-terminal protein product (p.Ala254Glyfs*3).","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/aa4597ba-9517-41f9-928d-979dfa309cca_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/27270174","allele":{"id":"https://genegraph.clinicalgenome.org/r/0e86afe9-79e5-478b-8e7e-686c7af386e3","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NC_000009.12:g.27172749T>C (GRCh38)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA373124808"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":1.5}],"specifiedBy":"GeneValidityOverallGeneticEvidenceCriteria","strengthScore":12},{"id":"https://genegraph.clinicalgenome.org/r/20f13e3f-f927-46c1-b5ed-919f696a7687_experimental_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/20f13e3f-f927-46c1-b5ed-919f696a7687_model_rescue_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/86215001-c987-4b77-b6f4-0bec43997e8e","type":"EvidenceLine","dc:description":"TEK-deficient mouse models form an excellent phenotypic match and parallel the mode of inheritance of the human patients.","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/90923d4f-42c2-43d4-b63b-2f05da85651c","type":"Finding","dc:description":"The mice match the human patients in that they exhibit abnormality of Schlemm's canal (convolutions and narrowing, Figure 5A) and increased intraocular pressure (Figures 5C, 6B, 6C). In addition to the defects in Schlemm's canal formation, the trabecular meshwork is also hypoplastic (Figure 7). The mice match the mode of inheritance from the human patients. A follow-up article confirms these findings and finds that Schlemm's canal maintenance in adult mice is also dependent on TEK, and that TEK dysfunction impairs aqueous humor outflow (PMID: 28920924 Figures 5 and 6).","dc:source":"https://pubmed.ncbi.nlm.nih.gov/27270174","rdfs:label":"Mouse model with heterozygous disruption of the TEK ortholog","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"}}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":3},{"id":"https://genegraph.clinicalgenome.org/r/6e9ee575-10e3-48c4-94c5-70c3fc2f067a","type":"EvidenceLine","dc:description":"The model has been scored at a reduced level despite its recapitulation of human ocular morphology and the intraocular pressure phenotype because the related mouse model with monoalleic disruption of *Tie2* has already been scored (PMID: 25202984).","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/aa86bfc2-eeb8-47d0-a6b7-411efe573c75","type":"Finding","dc:description":"The mice match the human patients in that they exhibit buphthalmos (similar to enlarged cornea and corneal edema), enlarged anterior chamber, and increased intraocular pressure (Figures 1E, 1H, and 1K).","dc:source":"https://pubmed.ncbi.nlm.nih.gov/25202984","rdfs:label":"Mouse model with homozygous disruption of the TEK ortholog","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"}}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityOverallModelAndRescueEvidenceCriteria","strengthScore":3.5},{"id":"https://genegraph.clinicalgenome.org/r/20f13e3f-f927-46c1-b5ed-919f696a7687_functional_alteration_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/ecf43aa0-8a00-4abf-96e9-5fa2a8d88f67","type":"EvidenceLine","dc:description":"This experiment indirectly implicates TEK in the regulation of the lymphatic endothelial cell fate through its downstream effector PROX1, which is relevant to the development and maintenance of Schlemm's canal (known to be TEK-dependent and related to aqueous humor draining, intraocular pressure and glaucoma).","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/7b4a7b81-de4c-4106-b5ca-8ea51df038a1","type":"FunctionalAlteration","dc:description":"Figure 1 indicates that TEK expression precedes PROX1 expression in Schlemm's canal. Figure 13 indicates that TEK promotes PROX1 expression at the mRNA and protein levels. Collectively, these data support the idea that TEK contributes to the development and maintenance of Schlemm's canal through a signaling pathway that promotes the activity of the transcription factor PROX1, which positively regulates lymphatic cell fate.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/28920924","rdfs:label":"TEK silencing triggers PROX1 downregulation"}],"specifiedBy":"GeneValidityNonPatientCellFunctionalAlterationCriteria","strengthScore":0.25}],"specifiedBy":"GeneValidityOverallFunctionalAlterationEvidenceCriteria","strengthScore":0.25},{"id":"https://genegraph.clinicalgenome.org/r/20f13e3f-f927-46c1-b5ed-919f696a7687_functional_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/8747fb7c-afd8-4f56-b689-61cca1f58172","type":"EvidenceLine","dc:description":"This evidence indicates that TEK is a receptor tyrosine kinase activated by ANGPT1 to promote cell-cell contacts and transduce signals through phosphorylation of itself and downstream targets such as AKT. These events appear to regulate endothelial cell behavior and are therefore relevant to the role of TEK in the development and maintenance of Schlemm's canal.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/839432d2-57dc-4859-b6b2-6ef1a939759e","type":"Finding","dc:description":"This evidence demonstrates the role of TEK as a receptor for ANGPT1 signaling, a mediator of cell-cell contacts, an upstream kinase in signal transduction cascades, and a regulator of endothelial cell behavior. These are all consistent with a function in the formation of Schlemm's canal, an endothelial structure responsible for aqueous humor drainage in the eye.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/18425120","rdfs:label":"TEK is an ANGPT1-stimulated receptor tyrosine kinase","demonstrates":{"id":"cg:BiochemicalFunctionB"}}],"specifiedBy":"GeneValidityBiochemicalFunctionCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/cc655e4e-5197-47fd-883c-c35fc6229c43","type":"EvidenceLine","dc:description":"This expression profile is consistent with a role for TEK in anterior chamber vascular development. This does not conflict with other evidence that TEK expression is restricted / specific to endothelial cells (PMID: 7835909), as this cell type forms Schemm's canal.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/c9f6a5ac-2158-4205-835c-b4cbd008b15b","type":"Finding","dc:description":"RNA-seq data from diverse human tissues indicate that TEK expression levels peak in adult retina. Fluorescent microscopy data from another paper confirm that TEK expression is high within the endothelial cells of Schlemm's canal in particular (PMID: 25051267).","dc:source":"https://pubmed.ncbi.nlm.nih.gov/30239781","rdfs:label":"TEK expression is highest in adult retinal tissues.","demonstrates":{"id":"cg:GeneExpressionA"}}],"specifiedBy":"GeneValidityGeneExpressionCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityOverallFunctionalEvidenceCriteria","strengthScore":1}],"specifiedBy":"GeneValidityOverallExperimentalEvidenceCriteria","strengthScore":4.75}],"evidenceStrength":"Definitive","sequence":5355,"specifiedBy":"GeneValidityCriteria9","strengthScore":16.75,"subject":{"id":"https://genegraph.clinicalgenome.org/r/25Nb2hPguNc","type":"GeneValidityProposition","disease":"obo:MONDO_0800182","gene":"hgnc:11724","modeOfInheritance":"obo:HP_0000006"},"version":"1.0","websiteLegacyID":"https://genegraph.clinicalgenome.org/r/assertion_20f13e3f-f927-46c1-b5ed-919f696a7687-","@context":{"@vocab":"https://genegraph.clinicalgenome.org/terms/","id":"@id","type":"@type","cg":"https://genegraph.clinicalgenome.org/terms/","dc":"http://purl.org/dc/terms/","obo":"http://purl.obolibrary.org/obo/","hgnc":"https://identifiers.org/hgnc:","rdfs":"http://www.w3.org/2000/01/rdf-schema#","cggv":"https://genegraph.clinicalgenome.org/r/gci/","evidenceStrength":{"@type":"@vocab"},"calculatedEvidenceStrength":{"@type":"@vocab"},"computedEvidenceStrength":{"@type":"@vocab"},"specifiedBy":{"@type":"@vocab"},"evidence":{"@container":"@set"},"disease":{"@type":"@vocab"},"gene":{"@type":"@vocab"},"phenotypes":{"@type":"@id"},"agent":{"@type":"@id"},"role":{"@type":"@vocab"},"modeOfInheritance":{"@type":"@vocab"},"sex":{"@type":"@vocab"},"direction":{"@type":"@vocab"},"ageType":{"@type":"@vocab"},"ageUnit":{"@type":"@vocab"},"dc:source":{"@type":"@id"},"curationReasons":{"@type":"@vocab","@container":"@set"},"GCISnapshot":{"@type":"@id"},"dc:isVersionOf":{"@type":"@id"},"websiteLegacyID":{"@type":"@id"}}}